An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: The COSTANza study

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 125-135

  Lazzaro, Carlo ^a   Bordonaro, Roberto ^b   Cognetti, Francesco ^c   Fabi, Alessandra ^c   De Placido, Sabino ^d   Arpino, Grazia ^d   Marchetti, Paolo ^e   Botticelli, Andrea ^e   Pronzato, Paolo ^f   Martelli, Elisa ^g  

^a Studio di Economia Sanitaria   (Italy)

^b Medical Angiology Unit Hospital Garibaldi   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g Government and External Affairs   (Italy)

Author keywords

Conventional paclitaxel; Cost effectiveness analysis; Italy; Metastatic breast cancer; Nab paclitaxel

Indexed keywords

PACLITAXEL;

ANEMIA; ARTHRALGIA; ASTHENIA; BREAST CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; ITALY; METASTASIS; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCORING SYSTEM; SENSITIVITY ANALYSIS; STOMATITIS; VOMITING;

EID: 84876173108     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S41850     Document Type: Review

References (50)

1. Grande E, Inghelmann R, Francisci S, et al. Regional estimates of breast cancer burden in Italy. Tumori. 2007;93(4):374-379.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM [homepage on the Internet]. Cancer incidence and mortality worldwide: IARC CancerBase No 10. Lyon: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr/factsheets/populations/factsheets.asp?uno=380#WOMEN. Accessed September 13, 2011.
3. The National Institute for Health and Clinical Excellence (NICE). Advanced Breast Cancer: Diagnosis and Treatment-Evidence Review. (CG81). London: The National Institute for Health and Clinical Excellence; 2009. Available from: http://www.nice.org.uk/nicemedia/live/11778/44046/44046.pdf. Accessed October 14, 2011.
4. National Comprehensive Cancer Network (NCCN) [homepage on the Internet]. Practice guidelines in oncology V2.2010: breast cancer. Available from: http://www.nccn.orgprofessionals/physician_gls/pdf/breast.pdf. Accessed October 14, 2011.
5. Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041-1053.
6. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs. 2008;19(9):899-909.
7. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2(2):59-64.
8. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263-1268.
9. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665-685.
10. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37(13):1590-1598.
11. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794-7803.
12. European Medicines Agency (EMA). Abraxane (paclitaxel) [homepage on the Internet]. London: European Medicines Agency; 2009. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000778/human_med_000620.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125&jsenabled=true#product-info/. Accessed October 14, 2011.
13. McLeod E, Samyshkin Y, Lloyd A, Prunieras F, Canney P. A UK cost-effectiveness analysis of paclitaxel albumin compared to solvent-based paclitaxel monotherapy and docetaxel monotherapy for pretreated metastatic breast cancer (MBC). Proceedings of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th Annual European Congress; November 6-9, 2010; Prague, Czech Republic.
14. Gold MR, Siegel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
15. Drummond MF, Schulper MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Oxford: Oxford University Press; 2005.
16. European Medicines Agency (EMA). Abraxane. Summary of Product Characteristics. London: European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000778/WC500020435.pdf
17. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338.
18. All Wales Medicines Strategy Group. Final Appraisal Report. Paclitaxel albumin (Abraxane®). Abraxis BioScience Limited. Advice No: 0410-April 2010; 2010. Available from: http://www.wales.nhs.uk/sites3/docopen.cfm?orgid=371&ID=158203&968E7C18-E3AD-FBDF-0929282839779CBA. Accessed October 14, 2011.
19. Scottish Medicines Consortium (SMC). Paclitaxel Albumin Powder for Suspension for Infusion (Contains 100 mg Paclitaxel as Paclitaxel Albumin) (Abraxane®) No (556/09). Abraxis BioScience Limited; 2010. Available from: http://www.scottishmedicines.org.uk/files/advice/paclitaxel_Abraxane_FINAL_March_2010_amended_For_Website.pdf. Accessed October 15, 2011.
20. Cooper NJ, Abrams K, Sutton AJ, Turner D, Lambert PC. A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer. J R Stat Soc Ser A Stat Soc. 2003;166(3):389-405.
21. Lohr SL. Sampling: Design and Analysis, 2nd ed. Boston: Brooks/Cole; 2010.
22. Ministero della Salute. Dipartimento Della Qualita'. Direzione Generale Della Programmazione Sanitaria, Dei Livelli Di Assistenza E Dei Principi Etici Di Sistema. Commissione nazionale per la definizione e l'aggiornamento dei Livelli essenziali di assistenza. Nuova caratterizzazione dell'assistenza territoriale domiciliare e degli interventi ospedalieri a domicilio. Roma: Febbraio 24, 2007. Italian.
23. Gazzetta Ufficiale Repubblica Italiana. Serie generale, n. 295 del 20/12/2006:31. Italian.
24. Gazzetta Ufficiale Repubblica Italiana. Serie generale, n. 241 del 14/10/2010:52. Italian.
25. Dialogo sui farmaci. Prontuario Commentato 2010. Verona: Dialogo sui farmaci srl, 2010. Italian.
26. Momento Medico. Farmabank 2011. Salerno: Momento Medico s.r.l., 2011. Italian.
27. Gerzeli S, Aguzzi G. Consumo di risorse e costi nei pazienti con carcinoma alla mammella metastatizzato HER2+. Italian Journal of Public Health. 2009;6(1 Suppl 1):S20-S30. Italian.
28. Ministero della Sanità. Decreto ministeriale n. 150 del 22Luglio 1996. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del Servizio sanitario nazionale e relative tariffe. Supplemento ordinario alla Gazzetta Ufficiale n. 216 del Settembre 14, 1996 Serie generale. Roma: Istituto Poligrafico e Zecca dello Stato, 1996. Italian.
29. Conferenza Permanente per i Rapporti tra lo Stato le Regioni e le Province Autonome di Trento e Bolzano. Tariffa Unica Convenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per l'anno 2008. Conferenza Permanente per i Rapporti tra lo Stato le Regioni e le Province Autonome di Trento e Bolzano. Roma: Conferenza Permanente per i Rapporti tra lo Stato le Regioni e le Province Autonome di Trento e Bolzano, Luglio 2009. Italian.
30. Regione Campania-Giunta Regionale-Seduta del 28 luglio 2006-Deliberazione N. 1034-Area Generale di Coordinamento-N. 19-Piano Sanitario Regionale e Rapporti con le UU. SS. LL.-N. 20-Assistenza-Sanitaria-Farmaci oncologici ad alto costo: rendicontazione tramite il file F. Napoli: Bollettino Ufficiale della Regione Campania, n. 40, settembre 4, 2006. Italian.
31. Fattore G per Gruppo di lavoro Associazione Italiana di Economia Sanitaria (AIES). Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia [A proposal for guidelines for the economic evaluation of health interventions in Italy]. Pharmacoeconomics-Italian Research Articles. 2009;11(2):83-93. Italian.
32. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986;292(6522):746-750.
33. Briggs AH. Handling uncertainty in economic evaluation. In: Drummond M, McGuire A, editors. Economic Evaluation in Health Care: Merging Theory with Practice. Oxford: Oxford University Press; 2001:172-214.
34. Capri S, Morabito A, Carillio C, et al. Valutazione economica di erlotinib, docetaxel e pemetrexed nel trattamento di seconda linea del carcinoma polmonare non a piccole cellule [Economic evaluation of erlotinib, docetaxel and pemetrexed as second line therapy in non-small cell lung cancer]. Pharmacoeconomics-Italian Research Articles. 2007;9(2):113-124. Italian.
35. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 1998;7(8):723-740.
36. Briggs A, Schulper M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
37. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.
38. Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health. 2002;23:377-401.
39. Willan AR, Briggs AH. Statistical Analysis of Cost-Effectiveness Data. Chichester: Wiley; 2006:51-57.
40. O'Hagan A, Stevens JW. The probability of cost-effectiveness. BMC Med Res Methodol. 2002;2:5.
41. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-787.
42. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approach to Clinical Trials and Health-Care Evaluation. Chichester: Wiley; 2004.
43. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making. 1998;18(Suppl 2):S68-S80.
44. Glick HA, Doshi JA, Sonnad SA, Polsky D. Economic Evaluation in Clinical Trials. Oxford: Oxford University Press; 2007.
45. Briggs A, Mihaylova B, Sculpher M, et al; for EUROPA Trial Investigators. Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. Heart. 2007;93(9):1081-1086.
46. Weinstein MC, O'Brien B, Hornberger J, et al; for SPOR Task Force on Good Research Practices-Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-Modeling Studies. Value Health. 2003;6(1):9-17.
47. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 2006;24(1):1-19.
48. Jönsson B. Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics. 2004;22 Suppl 4:5-10.
49. Mark DB, Hlatky MA, Califf RM, et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332(21):1418-1424.
50. Ufficio Italiano Cambi. Cambi giornalieri. Quotazioni in Euro [homepage on the Internet]. Available from: http://cambi.bancaditalia.it/cambi/cambi.do?lingua=it&to=cambiGForm. Accessed October 14, 2011. Italian.